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Abstract  
Despite extensive efforts to target mutated RAS proteins, anti-cancer agents capable of 
selectively killing tumour cells harbouring KRAS mutations have remained unavailable. Here, 
we demonstrate the direct targeting of KRAS mutant DNA using a synthetic alkylating agent 
(pyrrole-imidazole polyamide indole-seco-CBI conjugate; KR12) that selectively recognises 
oncogenic codon 12 KRAS mutations. KR12 alkylates adenine N3 at the target sequence, 
causing strand cleavage and growth suppression in human colon cancer cells with G12D or 
G12V mutations, thus inducing senescence and apoptosis. In xenograft models, KR12 
infusions induce significant tumour growth suppression, with low host toxicity in 
KRAS-mutated but not wild-type tumours. This newly developed approach may be applicable 









 Recent advances in the next-generation sequencing of human tumours have 
uncovered hundreds of recurrent oncogenic driver mutations and have identified many novel, 
actionable therapeutic targets. Oncogenic driver genes, which are often mutated, are 
continuously expressed and thereby contribute to cancer cell survival, which is a target for 
clinical therapy. Targeting the RAS-MAPK pathway has led to the development of successful 
treatments of EGFR-mutant cancers but has also revealed that unexpected degrees of 
oncogene addiction and signalling complexity exist 
14
. A common outcome of treatment using 
inhibitors of genes that lie “downstream” in the RAS pathway is the development of drug 
resistance 
16
, and new approaches that target mutant RAS genes may provide a more direct 
route to inhibit these poor-prognosis tumours. 
  RAS genes, particularly H-ras, N-ras, and K-ras, were the first human oncogenes to 
be discovered in human tumours more than 30 years ago and are among the most commonly 
mutated and critical cancer driver genes. The legendary K-Ras protein has been on everyone’s 
“target” list since its discovery. It has been estimated that approximately 33,000 newly 
diagnosed colon cancer patients in the United States during the year 2013 had the KRAS 
(G12D) mutation, which is considered the most frequent mutation in metastatic colon cancer, 
or the (G12V) mutation 
12,19
. Extensive efforts have therefore been made to develop one or 
more small chemical compounds that could directly target and inhibit constitutively active 
KRAS. Unfortunately, direct pharmacological targeting of activated KRAS has, to date, been 
unsuccessful for clinical use 
25
. Recently, a G12C KRAS mutation has been successfully 
targeted in vitro by a small molecule that allosterically controls GTP affinity and effector 
interactions, representing a promising approach to therapy for this specific subset of KRAS 
mutant tumours 
13
. In the face of the challenges in developing small-molecule drugs that 
directly target KRAS mutant proteins 
17
, we have developed a novel approach that directly 
targets the mutant DNA. Hairpin pyrrole (Py)-imidazole (Im) (PI) polyamides can be 
designed to bind with high affinity to the minor groove of specific DNA sequences 
6
: Py 
moieties preferentially bind T, A and C bases, but not G, whereas Im is a G-reader. These 
agents have shown efficacy in preclinical animal models of human diseases, including cancer, 
with minimal toxicity 
11,21,24
. For example, PI polyamide conjugates with 
1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-e]indol-4-one (CBI), which is converted to its 
cyclopropyl form via cyclisation of a precursor containing a chloro-methyl group to alkylate 
target DNA at the minor groove of N3 of adenine under neutral pH conditions, is a synthetic 
analogue of the alkylating moiety of duocarmycin A and can improve the limitations of 
targeting a coding sequence 
3,22,23
. We therefore synthesised PI polyamide indole-seco-CBI 




KR12 targets KRAS codon 12 (G12D and G12V) mutants  
 The compounds IPIIPI--PIPP-indole-seco-CBI (KR12: Fig. 1 (a)) and 
IIPIPI--PIPP-indole-seco-CBI (#6) 18 were designed and synthesised to recognise and 
alkylate adenine residues on the template strand of exon 2 of mutant KRAS, specifically at 
codon 12 (GTT and GAT) and codon 13 (GAC), respectively, according to the general 
recognition rule for PI polyamides 
6
. The hairpin PI polyamide for KR12 but not for #6 
preferentially bound to the mutant KRAS sequences, compared with wild-type, as shown by 
gel shift and Surface Plasmon Resonance assays (Supplementary Fig. 1 and 2, and 
Supplementary Table 1). Alkylation of theoretical recognition sequences, i.e., 
5’-WCGCCWWCA-3’ for KR12 and 5’-WCGWCWCCA-3’ for #6 (W indicates A or T), was 
confirmed using a thermally induced strand cleavage procedure 
18
. Dose-dependent, 
alkylation-mediated selective DNA strand cleavage was detected at the G12D/G12V 
mutations in the presence of KR12 (Fig. 1 (b)), and #6 showed specific cleavage of the 
sequence at the codon 13 mutation 
18
. Strong, dose-dependent alkylation by KR12 was 
detected only at the mutated KRAS codon 12 target sites among approximately 160 base pairs 
of KRAS EXON2 plus plasmid sequences, which did not have additional full-match 
recognition sites of KR12.  
The KR12-induced cell growth inhibition of a series of KRAS mutated or non-mutated 
human colon cancer cell lines, i.e., HT29 (WT), Caco-2 (WT), SW1463 (12C/12C; 
GGT-TGT), SW480 (12V/12V; GGT-GTT), SW620 (12V/12V) and LS180 (12D; 
GGT-GAT/WT), were then analysed using the standard WST (water soluble tetrazolium salts) 
assay. The viability of KRAS G12D or G12V mutant cells was significantly lower after 
treatment compared to wild-type cells or SW1463 cells carrying the G12C mutation, which is 
not recognised by KR12 (Fig. 2 (a)) (see also additional data on cell lines SNU-C2B 
(12D/12D) and DLD1 (13D/WT) in Supplementary Table. 2). A distinct pattern of cell 
viability was observed after KR12 treatment. Cell lines with KR12-recognised KRAS 
mutations (12D or 12V) were more sensitive than cell lines without those sequences, while 
there was no correlation between cell growth and p53 mutation status.  
 
Mutant KRAS suppression induced by KR12 
   To analyse the specific alkylation and subsequent downregulation of the KRAS 
mutant allele after KR12 treatment, human colon cancer-derived, heterozygously mutated 
LS180 (12V/WT) cells were used to evaluate allele-specific suppression after DMSO, KR12, 
#6 or KR12 lacking seco-CBI (Dp) treatment. Endogenous DNA alkylation at the KRAS 
codon 12 mutation in LS180 cells after KR12 but not after #6 or DMSO treatment was 
repeatedly confirmed using ligation-mediated PCR (Supplementary Fig. 3). Unlike DMSO-, 
#6- or Dp-treated cells, KR12-treated cells showed significant downregulation of total KRAS 
and mutated KRAS allele expression by quantitative rtPCR and colony PCR/sequencing 
assays, respectively (Fig. 2 (b) and (c), and supplementary Table 3). Immunoblot analysis also 
revealed that KR12, but not #6, induced a significant reduction in KRAS protein levels and in 
its GST-Raf-bound, active GTP-bound form, whereas KR12 had an undetectable effect on 
KRAS levels or activity in HT29 cells harbouring wild-type KRAS (Fig. 2 (d)). In contrast to 
KR12, Dp had an undetectable effect on KRAS codon 12 mutant expression, indicating that 
the targeted hairpin PI polyamide lacking the CBI alkylating moiety was not sufficient to 
reduce the expression of the targeted mutant gene (Fig. 2 (b)). Induction of 12V mutation 
sequence-specific alkylation after KR12 treatment could induce specific reductions in mutated 
KRAS RNA and activated KRAS protein levels in heterozygous LS180 cells.  We also 
observed slight reduction of KRAS downstream proteins of phospho-AKT and phospho-ERK 
expression after KR12 treatment (Supplementary Fig. 4 (d)).  
 
Senescence and DNA damage induced by KR12 in LS180 cells 
  We next investigated the biological effects of KR12 on KRAS mutant colon 
carcinoma cells. After 48 hours of 100 nM KR12-treatment, a flat cell morphology was 
displayed in LS180 cells, and SA--gal activity was strongly increased compared to DMSO- 
or #6-treated cells, suggesting that KR12 induced cellular senescence (Fig. 3 (a)). Cellular 
senescence is a stress response that stably blocks proliferation induced by activation of the 
RAS pathway, but is dependent on the cellular context 
5
. Cell cycle arrest is a critical process 
in cellular senescence that is induced by the CDK inhibitor p21
WAF1/CIP1 4
, and 48-hour KR12 
exposure significantly increased the proportion of G2/M-phase cells (Fig. 3 (b)). In contrast, 
DMSO and #6 had less of an effect on cell cycle distribution, and none of the three treatments 
increased the number of sub-G1-phase cells or the level of apoptotic genomic DNA 
fragmentation (Fig. 3 (c)). KR12 markedly induced phosphorylation of p53 at Ser-15, 
p21
WAF1/CIP1
 and phosphorylated histone variant H2AXH2AX), whereas KR12-mediated 
cleavage of PARP at the 48 hour time point was not observed (Fig. 3 (d)). Phospho-p53 
(Ser-15) and H2AX inductions in KR12-treated cells were also visually confirmed by 
indirect immunofluorescence staining (Supplementary Fig. 4 (b)). We conclude that KR12 
promotes p53-dependent cellular senescence, which is an important tumour suppressor 
mechanism 
5
, as well as DNA double-strand breaks, but not apoptosis, after short-term 
treatment.  
 
p53 dependent apoptosis is induced by KR12 in LS180 cells 
 Strong induction of apoptosis was, however, observed in LS180 cells after fourteen 
days of continuous 50 nM KR12 treatment, as evidenced by the significant increase in 
sub-G1-phase cells shown by FACS analysis (Fig. 3 (b) and Supplementary Fig. 4 (a)) and 
typical DNA fragmentation (Fig. 3 (c)), while #6 induced G2/M arrest. LS180 cells, which 
carry hemizygous wild-type p53 
10
, showed marked induction of p53 in association with 
cleaved PARP accumulation and H2AX, while treatment with #6 resulted in faint p53 
activation without PARP cleavage (Fig. 3 (d)), implying that apoptosis induction by long-term 
KR12 treatment might be p53-dependent. The induction of p53 phosphorylation at Ser-15 and 
of H2AX was also visually confirmed by indirect immunofluorescence staining 
(Supplementary Fig. 4 (c)). Based on these data, we propose that treatment of LS180 cells 
with KR12, but not with #6, introduces DNA breaks at the KRAS locus and induces H2AX 
foci and senescence and that after extended exposure to the drug, apoptosis occurs.  
 
KRAS knockdown enhances DNA alkylator-induced cell death  
To confirm a possible synergy of DNA alkylator and KRAS suppression in LS180 
cells, we assessed LS180 growth inhibition after treatments with siRNA targeting KRAS, 
control siRNA, #6 (KRAS non-targeting PI polyamide-indole-secoCBI) and combinations of 
siRNAs and #6. Although single treatments with either KRAS siRNA or #6 with control 
siRNA resulted in reduced LS180 cell viability, 1 nM of KRAS siRNA induced a partial 
reduction of cell growth. When treated together with a low dose (0.3 nM) of #6, 1 nM of 
KRAS siRNA resulted in significantly higher cell growth reduction than samples treated with 
1 nM of control siRNA (Supplementary Fig. 5 (a) and (b)), implying that even partial 
reduction of KRAS and its downstream signals may sufficiently increase the sensitivity of 
alkylating agents in LS180 cells. KR12 also caused partial downregulation of the active 
KRAS mutant and of DNA alkylation induction; therefore, KR12 increases its own ability to 
induce DNA damage, which is followed by cell death, in a similar manner.  
 Preferential in vivo tumour growth reduction by KR12  
 The potential efficacy of KR12 in vivo was tested by weekly intravenous injection of 
DMSO or KR12 (320 g/kg) for 5 weeks into nude mice inoculated with HT29 (KRAS WT), 
LS180 (heterozygous 12D/WT), or SW480 (homozygous 12V) cells. Treatment was started 
when the tumour size reached 100 mm
3
 (Supplementary Table 4 and Supplementary Fig. 6 
(a)). KR12 injection had an undetectable effect on the growth of HT29 tumours, whereas a 
significant reduction of tumour growth, with minimum toxicity, was demonstrated for the 
SW480 (P=0.0009) and LS180 (P=0.0122) tumours upon significantly reducing KRAS 
expression in those tumours (P=0.0388) (Fig. 4 and Supplementary Figs. 6 (b) and 7 (b)). 
Even after cessation of treatment at 5 weeks, KR12-treated SW480 tumours consistently 
showed slower growth than the DMSO-treated controls (Supplementary Fig. 7 (a)). 
Furthermore, the KR12-treated SW480 tumours exhibited movable, hard fibrotic nodules. We 
also examined the same experiment using an alkylating agent of CBI itself and #6, which 
should not have performed specific alkylation at the KRAS 12D mutation. Although CBI 
showed a strong anti-tumour effect, this tumour growth reduction was slightly weaker than 
that from KR12 treatment, and #6 did not show any significant anti-tumour effects in the 
SW480 xenografted nude mouse model. It was also intriguing that mice treated with KR12, 
#6 or DMSO remained healthy during the experiment, while CBI-treated mice exhibited 




   Although other drugs have been developed against the RAS signalling pathway, they 
are mainly effective against cancers with wild-type KRAS and are often ineffective in the 
treatment of KRAS-mutated colorectal cancers 
20
. The PI polyamide-based alkylation strategy 
specifically downregulated constitutively active KRAS and efficiently suppressed the in vitro 
growth of several KRAS mutant cancer cell lines through the induction of DNA damage and 
cellular senescence followed by apoptosis. The in vivo growth of KRAS G12V/G12D mutant 
tumour xenografts was also efficiently suppressed by weekly injections of KR12 into mice 
bearing tumours induced by the inoculation of LS180 or SW480 cells. Therefore, KR12 is a 
promising anti-cancer drug candidate for unmet KRAS codon 12 mutant cancers. We propose 
that PI polyamide-mediated-specific silencing of mutant oncogenic driver genes may 
therefore facilitate the development of a pipeline of next-generation, molecular targeted 
therapeutic strategies that could be applied in combination with mutant driver gene 
identification by sequencing the exomes of human cancers as a route to “Precision Medicine” 
that is targeted at the individual patient.  
 Hairpin N-methylpyrrole(Py)-N-methylimidazole(Im) polyamide indole-seco-CBI 
conjugates 
3,22
 can be designed for specific 9-base-pair recognition of the genome following 
Dervan’s recognition rule, as seen in natural minor groove binders, which undergo hydrogen 
bonding to DNA 
6
. Under neutral pH, the open-ringed seco-CBI moiety is converted to CBI, 
which then alkylates the N3 of adenine in the DNA minor groove. When conjugated to PI 
polyamide indole, the conjugates increase sequence recognition specificity compared to 
conventional alkylating agents, which mainly recognise the N6 of guanine in the DNA major 
groove without recognising the genomic DNA sequence 
2,3,22,23
. Although indole, 
γ-aminobutyric acid (γ-turn) and beta-alanine linker may require optimisation to improve their 
specificity and sensitivity for sequence-specific alkylation, the recognition of specific 9-bp 
sites in the genome by KR12 allows for multiple recognition sites (approximately 9,121 sites 
in the human genome (GRCh38/hg38)), where the mutated KRAS site should be included for 
preferential alkylation.  
KR12 treatment resulted in a significant reduction of activated KRAS and a 
significant induction in DNA damage followed by cell death in KRAS-mutated colon cancer 
cells. We observed dose-dependent alkylation at the mutated sequences by CBI conjugates, 
with approximately a ten-fold difference in the dissociation constants of the mutant and 
wild-type allele sequences, a reduction of mutant KRAS expression in heterozygous LS180 
cells, endogenous alkylation of the KRAS mutant genome, and in vitro and in vivo growth 
reduction of tumour cells with the KRAS mutations. All together, these results suggest that 
the DNA sequence-specific alkylating activity of hairpin polyamide indole-seco-CBI 
recognises the match sequence instead of the mismatch site. The number of naked PI 
polyamides showing biological efficacy as single agents remains limited. Thus, one way to 
enhance the therapeutic potential of PI polyamides might be to conjugate them to 
small-molecule drugs, such as alkylating agents 
7, 8
. 
 In many clinical trials, chemotherapy and targeted therapy combinations result in 
better outcomes for patients and prolong overall survival. As KR12 is an alkylating agent 
targeting a restricted number of genomic regions, including the KRAS driver oncogene 
mutation, it appears suited for combination therapy between molecular targeted therapy and 
conventional chemotherapy. Because of the sequence-specific DNA recognition of KR12, the 
number of genomic regions that are alkylated by KR12 should also be dramatically reduced in 
comparison to conventional chemotherapy; therefore, the adverse effect of toxicity to normal 
cells may be remarkably reduced, as demonstrated in animal experiments (Supplementary Fig. 
7 (a)). Although potential off-target effects of KR12 should exist among the 9,121 estimated 
target sites in the reference human genome (GRCh38/hg38), this possibility may not be a 
major concern for cancer patients with poor prognosis and experience with conventional 
chemotherapy. Although many issues still remain to be addressed for the clinical development 
of PI polyamide-indole-seco-CBI, as usually seen in cases of drug development, targeting 
oncogenic driver genes for alkylation may promise a fruitful feature of cancer therapy for 
untreatable cancer patients with unfavourable prognoses. Extensive genomic sequencing of 
tumour and normal tissues may provide critical biomarkers to aid in finding appropriate 
cancer cases that should be treated by KR12 or another specific genome-targeting alkylator.  
 Tumour selectivity is another important issue for anti-cancer treatment. In contrast to 
traditional cytotoxic chemotherapies, which crudely target growth processes shared by normal 
and cancerous tissues, agents such as Imatinib mesylate (Gleevec) for BCR-ABL 
translocation that target genetic alterations underlying cancer often have mild toxicity because 
of their greater specificity for cancer cells 
9
. In addition to specificity to the cancer genome, PI 
polyamide has been reported to accumulate specifically in xenografted tumour tissue in some 
cases
 15
. These unique properties of PI polyamide conjugates provide a very efficient capacity 
for drug delivery, and its alkylating conjugate, which targets oncogenic somatic mutations, 
could reveal a superb selective advantage by specifically targeting cancer cells with the 
mutation. This possibility may also support the observed very specific and effective in vivo 
anti-cancer activity of KR12.  
  In conclusion, a synthetic PI polyamide alkylator conjugate of KR12 has been 
designed to target KRAS mutations and induce mutant KRAS suppression followed by 
tumour cell death in vitro and in vivo in an oncogenic mutation-specific manner. Thus, KR12 
is a possible candidate drug for colorectal patients with either the G12D or G12V mutation.  






 The compounds ImPyImImPyIm--PyImPyPy-indoleCBI (KR12), shown in Fig. 1 
(a), and ImPyImImPyIm--PyImPyPy-indoleCBI (#6) 18 were designed and synthesised as 
described previously 
2
. Briefly, PI polyamides were synthesised in a stepwise reaction using a 
previously described Fmoc solid-phase protocol 
3
 and a peptide synthesizer (PSSM-8, 
Shimadzu Industry) with a computer-assisted operation system on a 10-mol scale (9.8 mg of 
Fmoc--alanine Wang resin). After synthesis, 1 mL of 50% 1 N LiOH/NMP was mixed with 
the resin, and the mixture was heated at 55 ºC for 1 hour to detach the PI polyamides from the 
resin. The PI polyamides were then purified by high-performance liquid chromatography 
(HPLC) LC-20 (Shimadzu Industry) using a 10 mm x 150 mm Phenomenex Gemini-NX3u 
5-ODS-H reverse-phase column in 0.1% acetic acid in water, with acetonitrile as the eluent, a 
ﬂow rate of 10 mL/min, a linear gradient from 30% to 75% acetonitrile over 30 minutes, and 
detection at 310 nm. Collected KR12-COOH fractions were analysed by LC-MS. DIEA (0.5 
μL, 2.86 μmol) and PyBOP (1.0 mg, 1.95 μmol) were added to a solution of Py–Im polyamide 
carboxylic acid KR12-COOH (1.0 mg, 0.66 μmol) in NMP (100 μL), and the reaction mixture 
was stirred for 1 hour at room temperature. After conversion from KR12-COOH to the 
activated 1-hydroxybenzotriazole ester was verified by analytical HPLC (0.1% TFA/CH3CN 
30–75% linear gradient, 0-30 min), NH2-indole seco-CBI (0.6 mg, 1.58 μmol) was added to 
the reaction vessel, and the reaction mixture was stirred for 4 days at room temperature. The 
reaction mixture was subjected to HPLC purification (0.1% TFA/CH3CN 30–75% linear 
gradient, 0–30 min), and the peak fraction containing the product was collected. After 
lyophilisation, KR12 was produced as a white powder. 
 
 
High–resolution gel electrophoresis 
 5’-Texas Red-labelled DNA fragments containing the indicated KRAS codon 12 
mutations were incubated with the indicated concentrations of KR12 for 10 hours at room 
temperature, followed by the addition of calf thymus DNA. The reaction mixtures were then 
incubated at 90C for 5 minutes to cleave DNA strands at their specific alkylated sites. DNA 
fragments were then recovered by vacuum centrifugation, dissolved in loading dye, denatured 




 Human colon carcinoma-derived HT29 (WT), Caco-2 (WT), SW1463 (12C/12C), 
SW480 (12V/12V) and SW620 (12V/12V) cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with heat-inactivated 10% FBS, 100 units/mL of 
penicillin and 100 g /mL of streptomycin. Human colon carcinoma-derived LS180 
(12D/WT) cells were grown in Eagle’s minimum essential medium (MEM) containing 
heat-inactivated 10% FBS, 100 units/mL of penicillin and 100 g of streptomycin. All cell 
lines were cultured in a 37C humidified atmosphere containing 95% air and 5% CO2.  
 
Cell Proliferation Analysis 
 Cells were seeded at a final density of 3 x 10
3
 or 5 x 10
3
 cells/96-well plate and 
allowed to attach overnight. The cells were then treated with 0.125% DMSO (dimethyl 
sulfoxide), 50 nM KR12 or #6. Forty-eight hours after treatment, 10 l of WST-8 reagent 
(Dojindo) was added to each culture, and the reaction mixtures were incubated at 37C for 
another 2 hours. The absorbance readings for each well were performed at 450 nm using a 
microplate reader (MTP-310; Corona).  
 
Real-time reverse-transcriptase PCR 
 Total RNA was prepared using the RNAeasy plus mini kit according to the 
manufacturer’s instructions (Qiagen), and 0.5 g of the RNA was converted to cDNA using 
the SuperScript VILO cDNA Synthesis System (Invitrogen) according to the manufacturer’s 
protocols. The Q-PCR Master Mix and specific primer sets were used for SYBR Green-based 
quantitative PCR (Q-PCR) (Applied Biosystems). Three independent measurements were 
taken, and the amounts were estimated by extrapolation from a standard curve. Expression 
values were normalised against the expression of RPS18 and used as an endogenous control. 
The primer sets used in this study were as follows: KRAS, 
5’-GGAGAGAGGCCTGCTGAA-3’ (sense) and 5’-TGACCTGCTGTGTCGAGAAT-3’ 
(antisense); and RPS18, 5’-GAGGATGAGGTGGAACGTGT-3’ (sense) and 
5’-TCTTCAGTCGCTCCAGGTCT-3’ (antisense).  
  
RAS GTP Assay 
 Cells were washed twice in ice-cold PBS and lysed in Mg
2+
 lysis buffer (MLB; 
Millipore), and protein concentrations were measured using the Bio-Rad Protein Assay 
System (Bio-Rad). Equal amounts of cell lysates (500 g of protein) were mixed with 10 l of 
GST-Raf-conjugated agarose beads (Millipore) and incubated for 45 minutes at 4C. After 
incubation, the agarose beads were extensively washed in lysis buffer and boiled in 40 l of 
2x SDS-sample buffer for 5 minutes, and the supernatants were analysed by immunoblotting 
with anti-KRAS antibody (Abcam).  
 
Immunoblot Analysis 
   Equal amounts of cell lysates prepared from LS180 cells exposed to DMSO, KR12 
or #6 were separated by 10% SDS-polyacrylamide gel electrophoresis and electro-transferred 
onto polyvinylidene difluoride membranes (Immobilon-P; Millipore). The membranes were 
blocked with TBS-T (Tris-buffered saline plus 0.05% Tween 20) containing 5% non-fat dry 
milk. After blocking, the membranes were incubated with anti-KRAS (ab55391, Abcam, 
1:1000), anti-p21 WAF1 (sc-756, Santa Cruz Biotechnology, 1:1000), anti-p53 (sc-126, Santa 
Cruz Biotechnology, 1:4000), anti-phospho-p53 at Ser-15 (9284, Cell Signaling Technology, 
1:1000), anti-PARP (9542, Cell Signaling Technology, 1:1000), anti-H2AX (613402, 
BioLegend, 1:2000), anti-Actin antibody (A5060, Sigma, 1:2000), or anti-BAX (2774, Cell 
Signaling Technology, 1:1000) followed by incubation with the appropriate HRP (horseradish 
peroxidase)-conjugated secondary antibody (rabbit:7074, mouse:7076, Cell Signaling 
Technology). Following extensive washing in TBS-T, antibodies bound to the indicated 
proteins were visualised using enhanced chemiluminescence reagents (ECL; GE Life 
Sciences).  
 
Indirect Immunofluorescence Assay 
 LS180 cells treated with DMSO, KR12 or #6 were rinsed twice in ice-cold PBS and 
then fixed in 3.7% formaldehyde at room temperature for 30 minutes. After washing in PBS, 
the cells were permeabilised with 0.1% Triton X-100 in PBS at room temperature for 5 
minutes and then blocked with 3% bovine serum albumin (BSA) in PBS at room temperature 
for 1 hour. After washing in PBS, the cells were incubated with anti-phospho-p53 at Ser-15 or 
with anti-H2AX at room temperature for 1 hour, followed by incubation with 
FITC-conjugated anti-rabbit IgG or rhodamine-conjugated anti-mouse IgG (Invitrogen), 
respectively, at room temperature for 1 hour. The glass coverslips were washed in PBS and 
mounted with VectaShield containing DAPI (Vector Laboratories). Fluorescent images were 
captured using a confocal microscope (Leica).  
 
Flow Cytometry 
 Cell cycle distribution was examined by flow cytometric analysis with a FACScan 
flow cytometer (BD Biosciences) following the manufacturer's instructions. In brief, the 
attached and floating cells were collected and fixed in ice-cold 70% ethanol. The cells were 
then stained with a solution containing 50 g/mL of propidium iodide (PI) and 100 g/mL of 
RNase A in PBS at 37C for 30 minutes to determine the total DNA content. The cell cycle 
distribution was then analysed using a FACScan flow cytometer.  
 
Animal Tumour Models 
 The animal protocol was approved by Chiba Cancer Center Animal Ethics 
Committee. HT29 (WT), LS180 (12D/WT) or SW480 (12V/12V) cells were implanted s.c. 
into the dorsal flanks of 6-week-old female athymic mice (Supplementary Fig. 6 (a)). When 
the tumour volume reached 100 mm
3
, administration of a non-toxic dose of DMSO or KR12 
(320 g/kg body weight) was performed, and 5 subsequent weekly injections with DMSO or 
KR12 were administered through their tail veins. Tumour-bearing mice were euthanised at the 
indicated times over 12 weeks after the first administration or when the tumours exceeded 2 
cm in diameter.   
 
Statistical Evaluation 
 Statistical analyses of the experimental data were performed using Student’s t-test. 
The statistical significance of tumour growth between the treated and control groups was 
assessed using the statmod software package for R (http://wwww.r-project.org) 
1
. The initial 
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the manuscript, with input from the other authors. A.B. contributed critical comments to the 
experimental strategy and editing. A.T., together with K.H., performed the experiments 
described in Supplementary Fig. 3 and Supplementary Fig. 5.  
 
FIGURE LEGENDS 
Figure 1. Structure of KR12 and the sequence-specific cleavage of a DNA strand through 
KR12-dependent alkylation. (a), chemical structure of the PI polyamide seco-CBI conjugate, 
termed KR12. (b), schematic drawing of thermal-induced cleavage at the sites of KRAS codon 
12 mutations. The upper and lower panels represent the G12V;GTT and G12D;GAT 
mutations. Circles represent imidazole moieties, and arrows indicate the positions of 
KR12-dependent alkylation and cleavage. An increased level of specific cleavage products 
was seen with increasing doses of KR12 (from bottom to top, Fig. 1 (b)) 
 
Figure 2. KR12-mediated specific suppression of KRAS codon 12 mutants in human colon 
cancer cells. (a), WST assay. Human colon cancer cells expressing wild-type KRAS, 
including HT29 and Caco-2, or human colon cancer cells harbouring KRAS codon 12 
mutations, including SW1643, SW480, SW620 and LS180, were incubated with the indicated 
concentrations of KR12. Forty-eight hours after treatment, the per cent viable cells were 
examined by WST assay and depicted in a line graph. Error bars indicate the SDs of the data 
from triplicate experiments. (b), quantitative rtPCR analysis. Relative KRAS expression 48 
hours after treatment with DMSO, KR12, #6 or Dp was plotted as a bar graph. Error bars 
indicate the SDs of data from triplicate experiments. (c), allele-specific downregulation of 
KRAS codon 12 mutant: cDNA from the treated RNA was subcloned. Transfected 
antibiotic-resistant/colour-selected colonies were screened by colony PCR and direct colony 
sequencing methods. The number of colonies for the wild-type or codon 12 KRAS mutant 
allele of each treated group was counted and reported in the table. The percentages of 
wild-type and mutant KRAS sequences are also shown in parentheses. (d), immunoblot 
analysis. Immunoblots for anti-KRAS or anti-actin antibody (top and bottom panels, 
respectively) for LS180 (12D/WT) and HT29 (WT) cells 48 hours after the treatment with 
either control DMSO solution, KR12 or #6. The GST-Raf-bound proteins from each treated 
group were pulled-down and analysed by immunoblotting with anti-RAS antibody (middle 
panels).  
 
Figure 3. KR12-dependent induction of cellular senescence and apoptosis. (a), SA--gal 
staining. LS180 cells were exposed to DMSO, KR12 or #6 (at a final concentration of 50 nM). 
Forty-eight hours after treatment, phase-contrast microphotographs were taken (top panels), 
and the cells were washed in PBS, fixed in 2% formaldehyde plus 0.05% glutaraldehyde and 
incubated with SA--gal staining solution containing X-gal for 24 hours at 37C (bottom 
panels). (b), cell cycle distribution analysis. Forty-eight hours (top) and two weeks (bottom) 
after treatment, cells were subjected to FACS analysis, and the DNA contents of each sample 
were analysed and depicted following the manufacturer`s instructions. (c), DNA 
fragmentation. The attached and floating LS180 cells 48 hours (left) and two weeks (right) 
after treatment were collected, and their genomic DNA was prepared and analysed by 1% 
agarose gel electrophoresis with  λ/HindIII and -X174/HaeIII size markers. (d), 
immunoblotting. Forty-eight hours (left) and two weeks (right) after the treatment, whole cell 
lysates were prepared and subjected to immunoblotting with the indicated antibodies. Actin 
was used as a loading control.  
 
Figure 4. KR12 suppresses tumour growth in vivo. (a), The indicated human colon cancer 
cells, i.e., HT29 (WT), LS180 (12D/WT) and SW480 (12V/12V), were injected s.c. into 
BALB/c nude mice. When the tumour volume reached 100 mm
3
, DMSO or KR12 (320 g/kg 
body weight) was i.v. injected through the tail vein every 7 days. At the indicated times after 
administration, the tumour volume was calculated as the longest diameter x width
2
 x 0.5. The 
mean tumour volume, with SEs (open circles for DMSO and closed circles for KR12 
treatment), and mean body weight, with SEs (open triangles for DMSO and closed triangles 
for KR12 treatment), of the KR12-treated group and control group are plotted in a line graph 
with error bars (SEs). The numbers of animals used were 6 for HT29 (DMSO and KR12) and 
LS180 (KR12), 5 for LS180 (DMSO) and SW480 (KR12), and 8 for SW480 (DMSO). (b), 
images of the euthanised mice of each group are shown. An image of an SW480 xenograft 5 
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DNA binding between biotinylated hairpin DNAs and Pyrrole-Imidazole polyamides, 
KR12Dp and #6Dp.  a. Biotin-labelled hairpin oligos were designed and synthesised to 
generate double-strand DNA, including wild-type (GGT 12G) and two mutant (GAT 12D and 
GTT 12V) sequences. The WT (GGT) DNA was the 1 base mismatch sequence for KR12. 
The MUT (GAT) and MUT (GTT) sequences were full-match sequences for KR12.  b. 
KR12 and #6 have alkylating seco-CBI moieties. KR12Dp and #6Dp have DP to be used for 
the SPR assay. c. SPR assays for KR12Dp and #6Dp with either WT (GGT), MUT (GAT) or 
MUT (GTT) DNAs at concentrations of 12.5 nM, 25 nM, 50 nM, 100 nM, 200 nM, 400 nM, 
or 800 nM in HBS-EP buffer with 0.1% DMSO were performed. Sensorgrams of KR12Dp 
and #6Dp with each biotinylated hairpin oligo, i.e., (a) KR12Dp with WT (GGT), (b) 
KR12Dp with MUT (GAT), (c) KR12Dp with MUT (GTT), (d) #6Dp with WT (GGT), (e) 
#6Dp with MUT (GAT) and (f) #6Dp with MUT (GTT), are shown.  
 
  












Gel shift assays for sequence-specific binding of KR12-Dp targeting KRAS codon 12 
mutation sequences  a. Two FITC-labelled hairpin oligos for the wild-type and mutant were 
designed and synthesised to generate double-strand DNA, including WT (GGT) and MUT 
(GAT) sequences. Double-strand DNAs were generated by heat denaturation at 100°C for 5 
minutes in annealing buffer (10 mM Tris, pH 7.5–8.0, 50 mM NaCl, 1 mM EDTA) and 
subsequent slow cooling to room temperature for more than 120 minutes. b. The gel shift 
assay was performed as previously described 17. Briefly, 7.5 pmol of FITC-labelled 
oligonucleotides were incubated with 75 pmol of KR12Dp or #6Dp for 1 hour at 37ºC. The 
resulting complexes were separated by electrophoresis and visualised with the luminescent 
image analyser LAS-4000 (Fujifilm, Tokyo, Japan). KR12Dp and WT DNA complexes 
showed remarkable gel shifts, while the other complexes did not.   





Endogenous alkylation confirmed by Ligation-mediated PCR  LS180 cells were plated at 
a density of 5 × 105 cells/10-cm dish and exposed to 500 nM of KR12 or #6. Twenty-four 
hours after treatment, genomic DNA was extracted by phenol-chloroform extraction and 
ethanol precipitation, and the alkylated genomic DNA (1 μg) was heated at 98°C for 2 
minutes. First-strand synthesis was performed using Prime STAR HS DNA polymerase 
(TAKARA) with a first-strand primer (5’- TACGATACACGTCTGCAGTCAAC-3’). After 
phenol extraction and ethanol precipitation, the sample DNA was resuspended in 25 μL of 
water, and the resuspended DNA (4 μL) was subjected to ligation with pre-annealed linker 
DNAs (Linker 1: 5’-AGCACTCTCGAGCCTCTCACCGCA-3’ and Linker 2: 
5’-TGCGGTGAGAGG-3’) at 16°C overnight using a DNA ligation kit (DNA Ligation Kit, 
Ver 2.1, TAKARA). To detect the DNA fragment ligated with the linker, we performed PCR 
using a primer pair (5’-CACGTCTGCAGTCAACTGGAAT-3’ and 
5’-AGCACTCTCGAGCCTCTCA-3’) followed by nested PCR using a primer pair (5’- 
TTATGTGTGACATGTTCTAATATAGTCAC-3’ and 5’-CTCTCGAGCCTCTCACC-3’). a. 
PCR fragments were electrophoresed in a 4% agarose gel, and the expected PCR fragments 
were detected using an UV illuminator: #6 showed a short fragment of DNA, suggesting that 
the non-dose-dependent thermal cleavage site approximately 60 bp upstream of the mutation 
site was detected by this method. b. The amplified DNA fragment should have StuI restriction 
enzyme sites and should generate 57 new fragments after digestion by StuI. The fragments 
were confirmed by restriction enzyme digestion with StuI.  
b a 













































Cell cycle distribution after long-term treatment, DNA damage induction and KRAS 
downstream.  a. Two weeks after treatment with the control 0.125% DMSO solution, 50 
nM KR12 or #6, phase-contrast microphotographs of LS180 cells were taken and are shown 
(top panels). The adherent and floating cells were then collected and subjected to FACS 
analysis to determine the cell cycle distribution (bottom panels). b. LS180 cells were 
subjected to the same DMSO, KR12 or #6 treatments. Forty-eight hours after treatment, the 
cells were fixed and simultaneously incubated with polyclonal anti-Phospho-p53 at Ser-15 
(red) and monoclonal anti-γH2AX (green) antibodies. Cell nuclei were stained with DAPI 
(blue). Images were taken by confocal microscopy.  c. Two-week KR12 exposure-mediated 
accumulation of phospho-p53 at Ser-15 and γH2AX, detected by indirect 
immunofluorescence assays. LS180 cells were treated with DMSO, KR12 or #6 for two 
weeks and then fixed and simultaneously incubated with polyclonal anti-Phospho-p53 at 
Ser-15 (red) and monoclonal anti-γH2AX (green) antibodies. Cell nuclei were stained with 
DAPI (blue). Images were taken by confocal microscopy.  d. LS180 cells were treated with 
50 nM KR12 for 48 hours. Extracted proteins from the treated cells were subjected to 
SDS-PAGE and subsequent Western blotting. KR12 induced a slight reduction in KRAS, 
phospho-AKT and phospho-ERK expression.  







KRAS suppression enhance DNA alkylator induced cell growth arrest.  To knockdown 
the expression of KRAS genes, LS180 cells were transfected with 5 nM of the indicated 
siRNAs against mutated KRAS (Réjiba, et al., Cancer Sci 98(7): 1128–1136 2007) using 
Lipofectamine-RNAiMAX (Invitrogen) according to the manufacturer’s recommendations. 
Seventy-two hours after transfection, cell proliferation was assessed using a real-time cell 
imaging system (IncuCyte; Essens Bioscience). For co-treatment with #6, LS180 cells were 
transfected with siRNA against mutated KRAS (1 or 5 nM), and 24 hours after transfection, 
the cells were treated with the indicated concentration of #6 for 72 hours. 
a. The LS180 cells treated with 5 nM of KRAS siRNA showed nearly complete suppression 
of KRAS expression and cell growth in LS180 cells (top), while 1 nM of KRAS siRNA 
showed partial suppression of KRAS expression (50%) and cell growth (middle). The control 
siRNA (si-ctrl) did not suppress KRAS expression or cell growth (bottom). Non- and 
partial-KRAS suppression due to #6 treatment resulted in dose-dependent suppression of cell 
growth.  b. The Waterfall plot shows reduced viability of LS180 cells, and accordingly, 
significant growth inhibition (P=0.04) was observed after the administration of even low 
concentrations (0.3 nM) of #6 after pre-exposure with 1 nM of the KRAS siRNA for 24 hours. 
Error bars indicate the SDs of the data from triplicate experiments. 
 
  











Establishment of human colorectal cancer xenograft models and relative tumour growth 
inhibition by KR12.  a. A schematic figure of tumour cell implantation and inoculation and 
subsequent administration of KR12 is shown. The animals were euthanised when the tumours 
reached a maximum of 10% body weight or when an individual tumour or the sum of all 
tumours reached a size of 2.0 cm in diameter. The animals were also euthanised before this 
stage if they showed signs of distress, loss of body weight (20%) or departure from the 
normal behaviour during the study, as under the IACUC protocol.  b. The average relative 
tumour sizes, with error bars, were blotted every three days after the initial treatment for the 
Weeks after initial treatment Weeks after initial treatment 
LS180 xenograft model (left) and once a week for the SW480 (right) xenograft model. Open 
diamond dotted lines indicate the DMSO-treated group, and black square lines indicate the 
KR12-treated group. Error bars indicate the SEs of the data from the indicated number of 
animal experiments.  
  
































Tumour growth inhibition of SW480 xenograft model and inhibition of KRAS 
expression in xenografted tumours. Animal experiments were performed as described in 
Figure 4 and Supplementary Figure 6.  a. In this study, we added experiments using #6 (4 
animals) and indole-seco-CBI (4 animals) treatment to the human colorectal cancer SW480 
xenograft model as well as the KR12 (5 animals) and DMSO (8 animals) treatments. KR12, 
but not indole-seco-CBI, showed a significant reduction in tumour size over that of #6 
(P=0.0061). Indole-seco-CBI-treated animals showed no body weight gain and slight illness 
compared to mice treated with the DMSO control and to mice treated with PI polyamide 
indole-seco-CBIs (KR12 and #6). Vertical error bars indicate ± SEs.  b. Each of four LS180 
xenografted tumours, 48 hours after DMSO or KR12 treatment (4 animals each), was 
collected and subjected to RNA preparation followed by real time quantitative PCR 
experiments to assess KRAS gene expression using the same primer sets used in Figure 2. All 
four KR12-treated tumours showed lower KRAS expression levels than all four 
DMSO-treated tumours. Significant suppression of KRAS expression by KR12 is shown in a 
bar graph of the mean values of 4 expression analyses, with vertical bars representing the 




Supplementary Figure 8 
 
 
ESI-TOF mass spectra of KR12 
ESI-TOF mass was produced on a BioTOF II (Bruker Daltonics) mass spectrometer using a 
positive ionization mode. ESI-TOF mass spectra indicated the [M+2H]2+ ions of KR12: 
calculated 1885.7027, observed 1885.6984 
 
  
Supplementary Figure 9 
 
NMR spectra of KR12 
1H NMR spectra was recorded with a JEOL JNM ECA-600 spectrometer operating at 600 
MHz; the spectra were recorded in parts per million (ppm) downfield relative to 
tetramethylsilane used as an internal standard. The following abbreviations apply to spin 
multiplicity: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). 
1H NMR (600 MHz, DMSO-d6): δ = 11.67 (s, 1H), 10.44 (s, 1H), 10.36 (s, 1H), 10.34 (s, 1H), 
10.28 (s, 1H), 10.27 (s, 1H), 10.22 (s, 1H), 9.95 (s, 1H), 9.94 (s, 1H), 9.89 (s, 1H), 9.83 (s, 
1H), 9.82 (s, 1H), 9.37 (s, 1H), 8.12 (d, J = 8.2 Hz, 1H), 8.09 (brt, 2H), 8.03 (t, J = 5.5 Hz, 
1H), 7.97 (brs, 1H), 7.93 (brt, 1H), 7.86 (d, J = 8.9 Hz, 1H), 7.57 (s, 1H), 7.55 (s, 2H), 7.53 (s, 
1H), 7.50 (s, 1H), 7.49 (s, 1H), 7.43 (d, J = 8.9 Hz, 1H), 7.41 (s, 1H), 7.368 (s, 1H), 7.367 (t, J 
= 7.6 Hz, 1H), 7.29 (s, 1H), 7.27 (s, 1H), 7.22 (s, 1H), 7.20 (s, 1H), 7.18 (s, 2H), 7.11 (s, 1H), 
6.93 (s, 1H), 6.89 (m, 2H), 4.81 (t, J = 10.0 Hz, 1H), 4.57 (d, J = 11.0 Hz, 1H), 4.23 (brt, 1H), 
4.03 (m, 2H), 4.00 (s, 3H), 3.99 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 3.92 (s, 3H), 3.87 (s, 3H), 
3.86 (s, 3H), 3.85 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.29 (m, 2H), 2.61 (m, 2H), 2.55 (m, 2H), 
2.38 (m, 1H), 2.28 (t, J = 7.4 Hz, 2H), 2.18 (t, J = 7.9 Hz, 1H), 2.01 (s, 3H), 1.90 (m, 1H), 
1.80 (apparent quintet, J = 6.9 Hz, 2H), 1.64 (m, 1H) 
 
  
Supplementary Table 1. Summary table of the dissociation constants and BIACORE 














Dissociation equilibrium constants (KD) were calculated by fitting the resulting sensorgrams 
using a two-state reaction model. The KD values for KR12Dp with MUT (GAT) DNA and 
KR12Dp with MUT (GTT) DNA were calculated as 8.5×10-9 M and 1.71×10-8 M, 
respectively. Those KD values showed significantly higher binding affinity compared with the 
KD values for the mismatch binding, where the KD value for KR12Dp with WT (GGT) DNA 
was 1.14×10-7 M. However, the KD value for #6Dp with WT (GGT) DNA was identified as 
2.62×10-7 M, that for #6Dp with MUT (GAT) DNA was 2.27×10-7 M, and that for #6Dp with 
MUT (GTT) DNA was 2.47×10-7 M. The KD values for mismatch binding were significantly 
lower than the KD values for full-match binding.  
 
 
Supplementary Table 2. IC50 of KR12 in human colorectal cancer cell lines.  
 
Cell lines KRAS status KRAS P53 status KR12 IC50(nM) CBI IC50(nM) 
SW480 MUT G12V MUT 31 10 
SW620 MUT G12V MUT 17 10 
SNU-C2B MUT G12D MUT 57 18 
LS180 MUT G12D WT 42 17 
SW1463 MUT G12C MUT 178 20 
DLD-1 MUT G13D MUT/WT 153 13 
HT-29 WT WT MUT 102 25 
Caco-2 WT WT MUT 105 18 
 
Half maximal (50%) inhibitory concentration (IC50) values of KR12 and CBI in a series of 
colon cancer cell lines with a variety of KRAS mutations. Three independent experiments in 
96-well plates using the MTT method were performed, as described in Fig. 2 (a). The KRAS 
and p53 mutation statuses of each cell line are indicated. Light grey-coloured columns 
indicate cell lines with KRAS mutations recognised by KR12. 
 
 
Supplementary Table 3. Allele-specific expression, as shown by direct sequencing and 
colony PCR assays. 
Compounds 
Number of colonies (%) 
colony sequence  colony PCR 
WT MUT  WT MUT 
DMSO 19 (50) 19 (50)  17 (61) 11 (39) 
KR12 29 (67) 14 (33)  27 (73) 10 (27) 
#6 15 (41) 22 (59)  14 (52) 13 (48) 
* p < 0.05  
 
Fifty ampicillin-resistant white colonies with subcloned inserts from cDNA of each treated 
cell type were randomly selected. Plasmid DNA was purified from these colonies and 
analysed by standard PCR using primer sets specific for wild-type KRAS or KRAS codon 12 
mutant or by direct sequencing using the Sanger method for independent colony pick-ups. 
The numbers of colonies with wild-type (WT) or mutated (MUT) DNA sequences are 
indicated, with percentages in parentheses. Any colonies with ambiguous sequences were 
ignored in this study.  
 
 
Supplementary Table 4. Establishment of human colorectal cancer xenograft models. 
 
 Tumour doubling time (day) SD  Median survival (day) SD 
HT29 (KRAS WT) 23.7 19  64 16.3 
LS180 (12D/WT) 4.4 0.716  16.8 1.64 
SW480 (12V/12V) 15.3 7.35  56.3 24.3 
 
The eight human colorectal cancer cell lines used in this study were implanted into the right 
thighs of 6-week-old female mice. Three of the most appropriately and constantly inoculated 
cells (HT29, LS180 and SW480) were selected for this study, and five mice of each 
implantation group were tested for health status, body weight, tumour doubling time and 
median survival time. The table shows the tumour doubling time and median survival time, 
with the standard deviation of each cell line xenograft model. All animals maintained a 
healthy status without weight loss during the experiments, but the tumour did not outgrow the 
right thigh.  
